New Virus-Like particle COVID vaccine enters first human tests

NCT ID NCT04839146

Completed ⭐️ VACCINE ⭐️ Sponsor: Radboud University Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested a new COVID-19 vaccine called ABNCoV2 in 45 healthy adults who had never had COVID-19. The vaccine uses a virus-like particle to train the immune system, and some doses included an adjuvant to boost response. The main goals were to check safety and measure antibody levels two weeks after the first shot.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ABNCoV2 vaccine (virus-like particle with or without MF59 adjuvant)
What this could lead to: If successful, this could lead to a new type of COVID-19 vaccine that may offer strong protection with fewer side effects.
What could go wrong: This is a very early Phase 1 trial with only 45 people, so safety and immune response are still uncertain. The vaccine may not work as hoped in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

severe acute respiratory syndrome COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID19 SARS-COV-2 INFECTION SEVERE ACUTE RESPIRATORY SYNDROME

Contacts and locations

Locations

Radboud univserity medical center

Nijmegen, Gelderland, 6525GA, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.